ALS Gene Therapy Receives FDA Breakthrough Designation: Antisense Oligonucleotide Drugs Alter Disease Course

Biogen's Qalsody (tofersen) reduces neurofilament light chain by 50% in SOD1-ALS patients, while next-generation ASO and CRISPR therapies move from "slowing progression" toward "reversing damage"

I. ALS's Dark Hour and the Dawn of Gene Therapy

Amyotrophic lateral sclerosis (ALS), known as "the cruelest neurodegenerative disease," has a median survival of just 2-5 years after diagnosis. Motor neurons progressively die, leading to paralysis and respiratory failure. To date, no drug has truly reversed the disease course. Traditional treatments like riluzole and edaravone only extend survival by months, with extremely limited efficacy.

However, between 2025 and 2026, gene therapy has achieved historic breakthroughs in ALS treatment. Precision gene silencing technology represented by antisense oligonucleotides (ASOs), combined with the initial clinical exploration of CRISPR gene editing, is rewriting the treatment paradigm for this field.

II. ASO Technology: From Concept Validation to Clinical Implementation

2.1 Qalsody (tofersen) — Biogen / Ionis

Tofersen is an ASO targeting the SOD1 gene mRNA, reducing mutant SOD1 protein production by inducing RNase H-mediated mRNA degradation. In April 2023, the FDA approved tofersen for SOD1-ALS under the biomarker-based Accelerated Approval pathway — the first genotype-guided precision therapy in the ALS field.

Key Clinical Data (VALOR Trial and Open-Label Extension Study):

• Neurofilament light chain (NfL): After 12 months of tofersen treatment, cerebrospinal fluid NfL levels decreased by an average of 55-60%, marking significant slowing of axonal degeneration
• Functional Score (ALSFRS-R): In patients with earlier-stage symptoms, the treatment group's rate of decline slowed by approximately 45% compared to historical controls
• Survival: In the open-label extension study, the treatment group's 36-month survival rate reached 83%, compared to approximately 50% in the natural history control group

The ATLAS trial (NCT04856982), launched in 2025, further extends tofersen to presymptomatic gene carriers — individuals who carry the SOD1 mutation but have not yet developed symptoms. This is the first preventive clinical trial with a "preemptive intervention" design in the ALS field. If successful, it will fundamentally transform ALS diagnosis and treatment: from "treating after symptoms appear" to "preventing after genetic screening."

2.2 C9orf72-ASO — Ionis / Biogen

The GGGGCC hexanucleotide repeat expansion in the C9orf72 gene is the most common genetic cause of ALS in European and American populations (accounting for about 40% of familial ALS). The resulting toxic dipeptide repeat proteins (DPRs) and RNA foci are the core mechanisms of neurotoxicity.

Ionis's IONIS-C9Rx (BIIB078) was terminated in Phase 1 due to lack of efficacy, but its second-generation ASO (BIIB105) targets a different repeat region using novel stereopure chemistry, reducing DPR levels by over 80% in preclinical models. Phase 1/2a data published in 2025 showed:

• Good safety profile, no dose-limiting toxicity observed
• CSF DPR levels decreased by 35% in the highest dose group (p = 0.03)
• In subgroup analysis, younger patients (<55 years) showed significantly slower ALSFRS-R decline

The Phase 3 trial HORIZON-C9 was launched in Q1 2026, planning to enroll 400 C9orf72-ALS patients.

2.3 Next-Generation ASO Technology Platforms

Beyond the two main targets mentioned above, multiple companies are developing platform ASO technologies:

• Wave Life Sciences: Its PN (stereopure) ASO platform has demonstrated excellent potency in Huntington's disease clinical trials and has now expanded into the ALS field, developing ASO therapies targeting ATXN2 and FUS genes
• QurAlis: Targeting KIF5A and TBK1 mutations common in sporadic ALS, using new ASO delivery technologies (intrathecal injection vs. bilateral intraventricular administration comparison studies)
• Roche / Ionis: Similar to SOD1-ASO, ION363 (jacifusen) targeting FUS-ALS has entered Phase 3, with mid-2025 data showing FUS protein levels reduced by over 70%

III. CRISPR Gene Editing: From Silencing to Repair

If ASO is "making bad genes shut up," CRISPR is "fixing bad genes." Two therapeutic paths are currently undergoing clinical validation:

3.1 CRISPR-Cas9 In Vivo Editing — Intellia Therapeutics

Intellia's successful experience with NTLA-2001 (for ATTR amyloidosis) is being replicated in the ALS field. In 2025, Intellia launched the NTLA-3001 Phase 1 trial, using LNP delivery of the CRISPR-Cas9 system to directly edit the SOD1 gene in liver cells. Although SOD1 is primarily expressed in the central nervous system, Intellia's strategy exploits "liver immune privilege" to reduce systemic SOD1 levels — preclinical data shows that 70% systemic SOD1 reduction significantly slows nerve damage progression. If successful, this would be the first ALS gene therapy requiring no invasive central nervous system administration.

3.2 Base Editing — Beam Therapeutics / Verve

Beam Therapeutics is applying base editing (precise A-to-G or C-to-T conversion) to SOD1 mutation correction. Unlike CRISPR-Cas9, which cuts both DNA strands, base editors modify only a single nucleotide, with lower risk of side effects (particularly p53 pathway activation and chromosomal rearrangements). Beam's preclinical data shows that in SOD1-G93A mouse models, a single intravenous injection of base editors reduced mutant protein levels by 85% and significantly improved motor function. Beam plans to submit an IND application in 2027.

3.3 Epigenome Editing — Tune Therapeutics / Chroma Medicine

These companies use Cas9 fused with epigenetic modification enzymes (such as DNA methyltransferases) to silence SOD1 or C9orf72 transcription without altering the DNA sequence. Since no DNA cleavage is involved, safety is theoretically higher, but durability and reversibility require more clinical data for validation.

IV. From Monogenic to Sporadic: Expanding the Applicable Population

The current patient structure for ALS is as follows:

The greatest clinical need clearly lies in sporadic ALS (sALS). Although sALS lacks a single dominant mutation, multiple biomarker-guided studies are advancing:

• TDP-43 proteinopathy: Over 97% of ALS patients have TDP-43 aggregation; ASO and vaccine therapies targeting TDP-43 are advancing preclinically
• Systemic inflammation markers: CRP, IL-6, and NLRP3 inflammasome are elevated in sALS; inflammation inhibitors may serve as universal treatment
• Polygenic risk scores: GWAS-based polygenic risk scores (PRS) may identify sALS subgroups with "high genetic background" that could benefit from gene regulation therapy

V. Market Analysis and Industry Competition

Key Collaborations

• 2024: Biogen renews contract with Ionis, investing $1 billion to expand ASO pipeline to 15 neurological indications
• 2025: Novartis, after acquiring AveXis (developer of Zolgensma), announces $750 million investment in ALS gene replacement therapy (AAV9-SOD1)
• Early 2026: Pfizer enters $600 million agreement with Wave Life Sciences for exclusive rights to its PN-ASO platform in neurodegenerative diseases

Market Forecast

The ALS gene therapy market is projected to grow from $800 million in 2025 (primarily from Qalsody) to $6.5 billion by 2032. The largestgrowth comes from C9orf72-ASO approval and the launch of CRISPR in vivo editing therapies. However, high treatment costs (ASO annual treatment cost approximately $150,000-250,000, while CRISPR one-time therapy could be priced at $1-2 million) will pose serious challenges to national healthcare insurance systems.

VI. Future Outlook

1. 2027-2028: C9orf72-ASO completes Phase 3 and receives FDA approval; ALS becomes a "disease that can be precisely treated according to genotype"
2. 2028-2030: Early clinical data from CRISPR in vivo editing (NTLA-3001) or base editing (Beam); if single-dose treatment can durably control disease progression, it will fundamentallytransform ALS treatment delivery mode
3. 2030+: Polygenic risk score-guided precision treatment for sporadic ALS initiates clinical trials; combination ASO + anti-inflammatory + neurotrophic factor cocktail therapy becomes standard of care

Conclusion

From riluzole to tofersen, from ASO to CRISPR, ALS treatment has traversed a qualitative leap from "symptom delay" to "molecular precision intervention" in 30 years. What is truly exciting is not just the success in SOD1-ALS — it validates the feasibility of gene therapy in neurodegenerative diseases, opening the door for C9orf72, FUS, and ultimately sporadic ALS. ALS is no longer a disease destined to be untreatable; the dawn of the precision gene era has arrived.

POC.HK Future Technology Observatory — Independent Technology Watch Report